Logo
Hyaluronidase 1500iu (Hyalase) – SINGLE VIAL

Hyaluronidase 1500iu (Hyalase) – SINGLE VIAL

Hyalase

Injectable enzyme (prescription-only medicine)
  • Hyalase (hyaluronidase 1500 I.U. powder for solution for injection/infusion) is a UK Licensed prescription Only medicine with a Marketing Authorisation held by Wockhardt UK Ltd.
  • Manufactured according to Good Manufacturing Practice (GMP) for sterile injectable medicinal products.
  • Use must comply with MHRA regulations, national prescribing standards and local clinical governance policies.
  • Off Label use for dermal filler dissolution is permitted within professional and regulatory frameworks where it is in the patient’s best interests and informed consent is obtained.
Hyaluronidase 1500 I.U. powder for solution for injection/infusion

Description

Hyaluronidase 1500iu (Hyalase) – SINGLE VIAL is a prescription-only, sterile enzyme preparation containing 1500 international units of hyaluronidase as a freeze-dried powder for solution for injection/infusion. In general medical use, Hyalase temporarily depolymerises hyaluronic acid in connective tissue, increasing tissue permeability so that injections, local anaesthetics and subcutaneous infusions spread and are absorbed more easily, and excess tissue fluid or blood can be reabsorbed. In aesthetic practice, this single 1500iu vial is widely kept in clinic emergency kits and dissolving protocols, where it is used off-label by trained prescribers to break down hyaluronic acid dermal fillers for planned adjustments or urgent management of complications such as overfilling, asymmetry, product migration or suspected vascular occlusion.

Bnefits

  • Provides a standardised 1500iu dose of purified hyaluronidase for flexible reconstitution and dosing.
  • Temporarily increases tissue permeability, enhancing dispersion and absorption of compatible injected solutions.
  • Enables controlled enzymatic breakdown of hyaluronic acid dermal fillers when clinically indicated.
  • Serves as a key component of emergency protocols for suspected vascular compromise due to filler, helping dissolve obstructing hyaluronic acid to restore perfusion.
  • Supports elective adjustments of existing filler treatments, allowing refinement of contours and correction of asymmetries.
  • Single-vial presentation is convenient for stocking individual clinics for both emergency and elective dissolving.
  • Manufactured to pharmaceutical standards with a known safety and efficacy profile when used by trained professionals.

Indications

  • Enhancing permeation of subcutaneous or intramuscular injections, as per licensed indications.
  • Improving dispersion and absorption of subcutaneous infusions (hypodermoclysis), where clinically appropriate.
  • Increasing the spread and effect of compatible local anaesthetic solutions according to product labelling.
  • Promoting resorption of excess tissue fluids and blood (e.g. certain haematomas or extravasation events) where dispersal is desired.
  • Off-label aesthetic use by qualified prescribers for dissolving and adjusting hyaluronic acid dermal fillers, including management of overfilling, lumps and nodules, migration, contour irregularities and suspected vascular occlusion.

Composition

  • Active ingredient: Hyaluronidase 1500 International Units (I.U.) per vial (freeze-dried powder).
  • Excipients: manufacturer’s standard excipients for Hyalase freeze-dried powder (trace buffer components and processing agents as specified in the official product information).

Formulation

  • Pharmaceutical form: powder for solution for injection/infusion.
  • White, sterile, freeze-dried powder plug in a neutral glass vial/ampoule intended for reconstitution immediately prior to use.
  • Each unit contains 1500 I.U. hyaluronidase; typical reconstitution volume is around 1 ml with an appropriate diluent (e.g. water for injections or normal saline, or directly into the intended injection solution) in line with official guidance and clinical protocols.
  • Intended for parenteral administration (e.g. subcutaneous, intramuscular, or as an additive to infusion fluids or local anaesthetics) by healthcare professionals.

Packaging

  • Single sterile vial/ampoule containing 1500 I.U. hyaluronidase powder for solution.
  • Labelled with product name (Hyalase or equivalent), strength (1500iu), batch number and expiry date.
  • Supplied within an outer carton with a package leaflet when dispensed as a licensed medicine; resold in professional channels (e.g. as a single vial) for clinic stock under prescription.
  • Pack format is suitable for clinicians wishing to keep one emergency or elective dissolving vial in their practice.

Usage

  • For use only by appropriately qualified prescribers and healthcare professionals in a clinical environment (hospital, clinic or suitably equipped practice).
  • Immediately before use, reconstitute the 1500iu powder with an appropriate volume of diluent (typically ~1 ml of water for injections or normal saline, or directly into the compatible solution being injected) following the official Hyalase product information and local protocols.
  • In general medical use, dose, route and method (e.g. addition to hypodermoclysis fluids, co-administration with local anaesthetics, subcutaneous or intramuscular injection) must follow the Summary of Product Characteristics (SmPC) and institutional guidelines.
  • In aesthetic off-label use for dermal filler dissolution, reconstitute to the desired concentration using saline (with or without lidocaine), then inject intradermally or subcutaneously in small aliquots using appropriate technique (e.g. microbolus, fanning, or serial puncture) into or around the filler to be dissolved, following evidence-based protocols.
  • Always aspirate according to local practice when injecting in high-risk vascular areas and monitor continually for signs of vascular compromise.
  • Ensure that full emergency equipment and medications (including those for treatment of anaphylaxis) are immediately available.
  • Use the reconstituted solution promptly; discard any unused portion in accordance with local clinical waste regulations.
  • Provide patients with information on expected effects, potential risks and signs of adverse reactions, and arrange follow-up as needed.

Contraindications

  • Known hypersensitivity to hyaluronidase or to any excipients in the Hyalase formulation.
  • Use for intravenous injection (Hyalase should not be administered intravenously).
  • Use to reduce swelling of bites or stings.
  • Use at sites where infection or malignancy is present, due to risk of facilitating spread.
  • Use to enhance absorption and dispersion of dopamine and/or alpha-agonist drugs, which is specifically contraindicated in the official product information.
  • Use for anaesthetic procedures in cases of unexplained premature labour.
  • Caution in pregnancy and breastfeeding; generally avoided unless the potential benefit clearly outweighs any risk as assessed by the prescriber.
  • Not for self-administration by patients; must not be used outside appropriate clinical supervision.

Adverse Effects

  • Local injection-site reactions such as pain, erythema, swelling, tenderness, pruritus or bruising.
  • Oedema or localised tissue swelling, particularly in association with subcutaneous infusions.
  • Infrequent infections at the injection site if aseptic technique is not strictly followed.
  • Allergic reactions ranging from mild local hypersensitivity or urticaria to rare but serious systemic reactions including anaphylaxis requiring immediate treatment.
  • Periorbital oedema reported when used with local anaesthetics in ophthalmic procedures.
  • In aesthetic use, excessive or improperly targeted dosing can result in unwanted loss of soft tissue volume or altered contours due to breakdown of both filler and some native hyaluronic acid.

Storage Conditions

  • Store in accordance with the official product information, typically below 25°C and in a dry place.
  • Keep the vial/ampoule in the outer carton to protect from light until ready for reconstitution.
  • Do not freeze unless explicitly permitted by the manufacturer (generally not recommended).
  • Do not use after the expiry date printed on the packaging.
  • Once reconstituted, the solution should be used immediately and any remainder discarded safely.
  • Store out of the sight and reach of children.

Duration

The enzymatic effect of hyaluronidase is rapid and short-lived; it typically enhances tissue permeability and promotes dispersion and absorption over minutes to several hours. In filler dissolution protocols, noticeable softening and volume reduction often occur within the same session, with ongoing changes over the following hours to days as hyaluronic acid breakdown products are cleared.

Onset

Onset is usually rapid, with increased spread and absorption of injected solutions or softening of hyaluronic acid filler often observed within minutes to the first few hours after injection, depending on dose, depth, injection technique and tissue characteristics.

Browse more Injectable enzyme (prescription-only medicine)

Top Treatments

Top Cities in the UK